Gabapentin Capsule
Product Images NDC 71335-1484

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

This text appears to contain a formula for calculating something based on the age in years and weight in kilograms. It mentions creatinine levels for female patients, but the exact context or purpose is not clear. It seems to be a calculation related to medical or health data.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

This is a graph depicting the Mean Pain Score over the course of a study involving various treatments. The treatments included a placebo and Gabapentin at a dosage of 3600 mg/day. The graph shows the pain scores at different time points from baseline to week 7.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

This text seems to be related to a study or evaluation of pain scores under different dose periods for a medication called Gabapentin. The study compares the pain scores between a placebo group and two different doses of Gabapentin (1800 mg/day and 2400 mg/day) over a 4-week fixed dose period. The initial baseline pain score is also mentioned. However, further details are not available.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

This description shows the proportion of responders (patients with at least a 50% reduction in pain score) at the endpoint in controlled PHN studies. Study 1 indicates 32% responders for the placebo (PBO) group and 34% for the GBP 3600 group, while Study 2 shows 12% for the placebo group and 14% for the GBP 1800 group. The data suggests varying levels of response to the treatment based on the dosage of GBP administered.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

FDA Label Image

Chemical Structure (Gabapentin Str)

FDA Label Image

Label Image (Lbl713351484)

This is a label from a package of Neurontin 100mg capsules by Aurobindo Pharma Limited. The package contains 90 capsules and has an expiration date of MM/YY. The NDC number is 7133514841 and it should be stored at room temperature of 20°-25°C (68°-77°F). It is advised to keep all drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.